Epstein-Barr virus infection status among first year undergraduate university students
- 26 February 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of American College Health
- Vol. 70 (1) , 22-25
Abstract
Objective: Epstein-Barr virus (EBV) is the cause of infectious mononucleosis, which disproportionately affects university students. This population has the potential to benefit from a prophylactic EBV vaccine trial. Our objectives were to determine EBV infection status and associated demographic/lifestyle factors among first year undergraduate university students at the beginning and end of first year. Methods: EBV infection status was assessed by testing for circulating IgG class antibodies against EBV viral capsid antigen. Results: Of 198 starting students; 56.1% were positive for EBV antibodies with a higher rate in women (64.8%) than male (41.1%); p = 0.002. A history of deep kissing was associated with a higher rate of EBV antibody positivity. On follow-up 8 months later at the end of freshman year, 22.4% had acquired EBV antibodies for a primary infection incidence of 33.6/100 person years. Conclusion: These findings indicate that our first year undergraduate population contains sufficient EBV-naïve subjects for a prophylactic vaccine trial.Keywords
This publication has 16 references indexed in Scilit:
- Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its AcquisitionThe Journal of Infectious Diseases, 2013
- Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein–Barr Virus Infection in University StudentsThe Journal of Infectious Diseases, 2012
- Infectious Mononucleosis in University Students in the United Kingdom: Evaluation of the Clinical Features and Consequences of the DiseaseClinical Infectious Diseases, 2010
- Mononucleosis and Athletic Participation: An Evidence-Based Subject ReviewClinical Journal of Sport Medicine, 2008
- Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young AdultsThe Journal of Infectious Diseases, 2007
- A Cohort Study among University Students: Identification of Risk Factors for Epstein‐Barr Virus Seroconversion and Infectious MononucleosisClinical Infectious Diseases, 2006
- A Prospective Clinical Study of Epstein‐Barr Virus and Host Interactions during Acute Infectious MononucleosisThe Journal of Infectious Diseases, 2005
- Early primary infection and high Epstein‐barr virus antibody titers in greenland eskimos at high risk for nasopharyngeal carcinomaInternational Journal of Cancer, 1984
- VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMAThe Lancet, 1964
- THE TRANSMISSION OF INFECTIOUS MONONUCLEOSISThe American Journal of the Medical Sciences, 1955